NVCR Live signals | Maximize Profits with Getagraph.com

BUY 250 min ago

@ $13.06

Issued: 4 Dec 2023 @ 13:14

Return: -0.54%

Previous signal: Dec 1 - 15:31

Previous signal: Sell

Return: 5.20 %

Live Chart Being Loaded With Signals

Commentary (4 Dec 2023 @ 16:00):

Stats
Today's Volume	1.50M
Average Volume	1.48M
Market Cap	1.39B
EPS	$-0.460 ( 2023-10-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.98
ATR14	$0.970 (7.47%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-07	Shah Pritesh	Sell	382	Ordinary Shares
2023-10-31	Puri Michal Nath	Buy	57 604	Stock Option (Right to Buy)
2023-10-31	Puri Michal Nath	Buy	37 593	Ordinary Shares
2023-10-25	Puri Michal Nath	Buy	0
2023-11-02	Cordova Ashley	Buy	175	Ordinary Shares

INSIDER POWER
73.00
Last 96 transactions
Buy: 737 040 \| Sell: 116 982

Volume Correlation

Long: 0.06 (neutral)

Short: 0.98 (very strong)

Signal:(76) Expect same movement, but be aware

Novocure Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novocure Ltd Correlation - Currency/Commodity

0.01
( neutral )

-0.46
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.00
( neutral )

-0.16
( neutral )

Novocure Ltd Financials

Annual	2022
Revenue:	$537.84M
Gross Profit:	$422.97M (78.64 %)
EPS:	$-0.880

Q3	2023
Revenue:	$127.32M
Gross Profit:	$95.23M (74.79 %)
EPS:	$-0.460

Q2	2023
Revenue:	$126.05M
Gross Profit:	$92.03M (73.01 %)
EPS:	$-0.540

Q1	2023
Revenue:	$122.18M
Gross Profit:	$92.57M (75.76 %)
EPS:	$-0.500

Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.